ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Expected to Post Quarterly Sales of $73.07 Million

Equities research analysts expect ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to post $73.07 million in sales for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for ACADIA Pharmaceuticals’ earnings. The highest sales estimate is $76.50 million and the lowest is $69.25 million. ACADIA Pharmaceuticals reported sales of $57.06 million during the same quarter last year, which indicates a positive year over year growth rate of 28.1%. The company is expected to announce its next earnings results on Wednesday, August 14th.

On average, analysts expect that ACADIA Pharmaceuticals will report full-year sales of $292.84 million for the current year, with estimates ranging from $285.18 million to $299.40 million. For the next fiscal year, analysts forecast that the firm will report sales of $416.22 million, with estimates ranging from $358.50 million to $582.53 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.59) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($0.05). The firm had revenue of $62.90 million for the quarter, compared to analysts’ expectations of $60.93 million. ACADIA Pharmaceuticals had a negative net margin of 116.10% and a negative return on equity of 79.74%. The business’s quarterly revenue was up 28.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.44) earnings per share.

Several analysts have commented on the stock. Zacks Investment Research raised shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and set a $30.00 price target for the company in a research report on Tuesday, July 2nd. BidaskClub downgraded ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 18th. Needham & Company LLC reiterated a “buy” rating and set a $40.00 target price on shares of ACADIA Pharmaceuticals in a research report on Monday, July 1st. HC Wainwright reiterated a “buy” rating on shares of ACADIA Pharmaceuticals in a research report on Friday, May 3rd. Finally, ValuEngine downgraded ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Six equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $32.31.

A number of large investors have recently made changes to their positions in ACAD. FMR LLC increased its stake in ACADIA Pharmaceuticals by 14.9% during the fourth quarter. FMR LLC now owns 21,543,893 shares of the biopharmaceutical company’s stock worth $348,364,000 after acquiring an additional 2,792,885 shares during the last quarter. Great Point Partners LLC increased its stake in ACADIA Pharmaceuticals by 130.1% during the fourth quarter. Great Point Partners LLC now owns 2,752,256 shares of the biopharmaceutical company’s stock worth $44,504,000 after acquiring an additional 1,556,158 shares during the last quarter. Norges Bank acquired a new stake in ACADIA Pharmaceuticals during the fourth quarter worth about $15,717,000. Artisan Partners Limited Partnership increased its stake in ACADIA Pharmaceuticals by 348.2% during the first quarter. Artisan Partners Limited Partnership now owns 1,131,829 shares of the biopharmaceutical company’s stock worth $30,390,000 after acquiring an additional 879,311 shares during the last quarter. Finally, First Trust Advisors LP increased its stake in ACADIA Pharmaceuticals by 16.4% during the first quarter. First Trust Advisors LP now owns 4,815,776 shares of the biopharmaceutical company’s stock worth $129,304,000 after acquiring an additional 677,051 shares during the last quarter. Institutional investors own 93.35% of the company’s stock.

ACAD stock opened at $27.14 on Thursday. The firm’s 50-day moving average price is $25.64. ACADIA Pharmaceuticals has a one year low of $12.77 and a one year high of $28.67. The company has a quick ratio of 6.29, a current ratio of 6.35 and a debt-to-equity ratio of 0.02.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Further Reading: Day Trading

Get a free copy of the Zacks research report on ACADIA Pharmaceuticals (ACAD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.